Plain-English translation of NCT05568550 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether —an immunotherapy drug that helps your immune system fight cancer—works better when combined with radiation therapy and sometimes an additional medication called for men with high-risk prostate cancer. You would receive this medication alongside standard radiation and hormone therapy that is already known to help treat this condition. The researchers believe combining these treatments may work more powerfully together than any single approach.
High-risk prostate cancer can be difficult to treat with standard therapy alone. This trial exists because early research suggests that combining immunotherapy with radiation may boost the immune system's ability to attack cancer cells while also making the radiation more effective.
You likely qualify if…
You likely don't qualify if…
You would receive radiation therapy to your prostate combined with hormone therapy according to your hospital's standard approach. During this time and after, you would receive the immunotherapy medication (given as infusions over about a year) and, for the first few months, the additional medication (taken as pills). You would have regular clinic visits and blood tests to monitor how you're responding and watch for any side effects. The entire treatment course would last about one year.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States